[email protected]   +1 (304) 306-0723
Sale!

Chimeric Antigen Receptor (CAR-T) Cell Therapy – Market Opportunity, Pipeline & Competitive Intelligence 2020

$2,400.00$7,200.00

Chimeric antigen receptor (CAR) T-cell therapy has generated a great amount of interest and have encouraged investors to support development in the field of adoptive cellular immunotherapy. Over the past couple of years, there has been rapid progress in the field. Researchers are refining the safety and efficacy profiles of CAR T cells with new concepts and technologies. These will be therapies that will address current challenges through mechanisms of superior efficacy, safety and delivery.
Clear
SKU: MM202028 Categories: , , Tags: ,

Description

Chimeric Antigen Receptor (CAR-T) Cell Therapy has the potential to be a driver of growth through the introduction of new technologies and  mechanisms that solve current clinical and commercial  challenges, which ultimately can expand FDA approved  cell therapies. With cell and gene therapies emerging as innovative treatment options for many cancers and other rare diseases, there are currently thousands of cell and gene therapies in the development and commercialization pipeline. As a result, the FDA is preparing for the wave of experimental therapies, and by 2025, the FDA may approve 10 to 20 new cell and gene therapy products a year.
CAR-T Marketed Therapies Approval
CAR-T Marketed Therapies

“In the big picture, I think that this technology is a game changer. For the first time, we are seeing a powerful immune technology dramatically impact myeloma, even in [patients with] relapsed or refractory disease. This could lead at some point to a cure or give us clues to lead us in that direction.”

CAR-T Therapy Key Summary

  • Currently, there are five approved CAR-T cell therapies, namely KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences), TECARTUS ™ (Gilead Sciences) and BREYANZI® (Bristol Myers Squibb / Juno Therapeutics) and ABECMA (Bristol Myers Squibb).
  • Haematological Malignancy market in 2019 was ~ based on the Diffuse Large B-Cell Lymphoma Acute Lymphocytic Leukemia (<25 y.o.) was 0.7 billion and with the new indications in liquid tumors are currently under clinical development and could expand the market to an estimated $6.2 bn by 2030.
  • CD19 holds 100% market share in haematological malignancies in 2020. As BCMA-based CAR-T therapies enter the market beginning from 2021, the market share is expected to split to 72% (CD19)/ 28% (BCMA) by 2030
  • Currently, in 2021, Gilead holds the major market share of around 60% with its two products Yescarta and Tecartus. In 2030, BMS with its therapies, namely Breyanzi and Abecma, is expected to surpass Gilead’s sales and become the leader in the CAR-T therapy space.
Kymriah Forecast 2030
Kymriah Forecast 2030
  • Solid Tumors to Drive Market Expansion for Cellular Therapies
  • Around 76 Companies Collaborations in CAR-T Space have been observed in the past 8 years. CAR-T companies are on the rise, supported by growing investment flowing into CAR-T research, landmark approvals of CAR-T cell therapies by the U.S. FDA (Kymriah, Yescarta, Breyanzi, Tecartus and Abecma), and major collaborations within the CAR-T space.
  • There has been a total of $ 10 billion investment deals that have been seen in the CAR-T space for the past 8 years. The year 2018 saw the highest investment compared to other years of approximately USD 2.8 billion.

CAR-T Collaborations & Investments 2030

  • ~52 University & Companies Collaborations in CAR-T Space have been observed in the past 11 year
  • ~78 Acquisition Deals were observed in CAR-T Space have been observed from 2013 to 2020
  • Manufacturing Facilities for the Development of CAR-T cells have increased with approval of new CAR-T therapies as well as the expansion of the sites for the existing ones. For instance
    • Commercial manufacturing for Kymriah takes place at five sites globally including at the Morris Plains, New Jersey facility, where the US Food and Drug Administration (FDA) has also approved a further increase in manufacturing capacity in Dec, 2020. In 2020, Novartis made significant progress in expanding our global manufacturing capacity with a 70% increase compared to 2019 year.
    • Gilead purchased a new building in Santa Monica, California that were formerly owned by the Japanese pharma Astellas
    • BMS plans to manufacture Breyanzi for each individual patient at its state-of-the-art cellular immunotherapy manufacturing facilities, initially in Bothell, Washington and then also expanding to later manufacture it in Summit, New Jersey to support clinical and commercial capacity and accommodate patient geographic spread.
  • Allogeneic approaches could provide a workaround for lengthy manufacturing times. The pre-dominant leaders in allogeneic CAR-T space are Cellectis, Servier, Allogene, Autolus and Precision Therapeutics which have entered into the clinical stages. Allogene, Servier, and Cellectistechnology uses a healthy donor’s T-cells and engineers them to target the CD19 antigen and delivers those cells to the patient.
  • There are ~444 products in the Pre-clinical stage of development, representing 64% of the total share of the developing CAR-T landscape

CAR-T Competitive landscape 2030

  • The clinical staged CAR-Ts are dominated by biotech companies headquartered in China with the Chinese companies holding the top ten positions. They represent ~40% of all the pipeline CAR-Ts in clinical stages.
  • There are ~166 Companies presently developing CAR-T with CD19 & BCMA, together forming 43.8% share in the field of CAR T-cells therapy.
  • There are ~28 key next generation technologies based CAR-T therapies in the Clinical Stage of development in addition to the conventional CAR T-cell technologies
  • Bellicum Pharmaceuticals is a leading company with two interesting Safety Switch technologies –An emergency “kill” switch and Default state to off switch.
  • To be continued…

Report Coverage

The CAR-T report is a 1000 pager Report which provides an in-depth analysis of key market trends and governing factors along with market attractiveness by segments. The report also provides the qualitative impact of various market factors on various CAR-T market segments and geographies. The comprehensive information provided in this report will help companies identify better opportunities. The report covers the more than 300 companies with over 700 CAR-T therapies, which are active in this field targeting more than 95 different antigens and ~ 28 next-generation CAR-T technologies.
The Report provides in-depth analysis of CAR-T cell profiles covering preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and antigens, investments, and funding and acquisition trends. The Report provides CAR-T licensing opportunities, acquisition trends, Product analysis by phases, antigen type & indications. Furthermore, the report covers KOL’s views on CAR-T therapy. The report also estimates the size of the existing market and identifies potential growth opportunities for CAR-T cell therapies in the next decade in the 2021-2030 period. Strategists can gain detailed insight and devise appropriate strategies to target a specific market.

Report Highlights

  • Chimeric Antigen Receptor (CAR-T) Cell Therapy market potential based on Indications
  • Business Transactions & Strategies: Key collaborations and deal values
  • Chimeric Antigen Receptor (CAR-T) Cell Therapy Pipeline Development: Product Profiles, Clinical Trials & Results
  • Chimeric Antigen Receptor (CAR-T) Cell Therapy Acquisition Targets
  • Chimeric Antigen Receptor (CAR-T) Cell Therapy Competitive Intelligence
  • Recent & Upcoming event

Additional information

Price

2-3 User License, Enterprise License, Single User License, Site User License

Table of Contents

  • CAR-T Therapy Report Overview
  • Key Criteria for Success in CAR-T Therapies
  • The CAR-Therapy Introduction
    • Chimeric Antigen Receptor (CAR) T-cells Therapy Overview
      • CARS Generations
      • CAR-T Cell Therapy Design
      • Genetic Engineering of T-Cells
      • Necessity of 2nd Generation and 3rd generation CAR Signalling
      • Co-stimulatory domains
    • Challenges to the commercialization of CAR T-cell therapies
      • Complex manufacturing and supply chain
      • CAR T patient treatment journey
      • Reimbursement challenges for CAR T
    • Overcoming Challenges with CAR-T
      • Introduction of Advanced gene-transfer tools
      • Healthcare Settings to administer CAR-T
      • Rapid Innovation into Solid tumours
    • CAR-T Cell Therapy-Analysis
      • CAR-T Collaboration Deals
        • CAR-T Cells Therapy Collaborations and Deal Year
        • CAR-T Investment Analysis
        • Collaborations & Deal Value Trends
      • CAR-T Acquisitions Deals
        • CAR-T Cells Therapy Acquisitions Trends
        • CAR-T Cells Therapy Acquisitions Offerings
      • Manufacturing Facilities for the Development of CAR-T cells
    • Allogeneic CAR-T therapy: a promising approach in CAR-T space
    • CAR-T Licensing Opportunities
    • Pipeline Scenario
      • Pipeline Products under Development – An Overview
        • Pipeline Products under Development by Company
        • CAR-T cells Targeted Antigens
  • Pipeline Scenario
    • Target: CD19 Related Drug Products
    • Targets: Other than CD19, Related drug products
    • CAR T-cell Technologies & Companies Involved
    • CAR-T Safety Switches & Company Involved
  • Marketed Drug Profiles
    • Tisagenlecleucel (Kymriah)
    • Axicabtagene ciloleucel (Yescarta)
    • Brexucabtagene autoleucel (Tecartus)
    • Lisocabtagene maraleucel (Breyanzi)
    • Idecabtagene vicleucel (Abecma)
  • Market Sizing and Opportunity Analysis
    • Overall CAR-T Cell Therapy Market, 2021-2030
      • CAR-T Cell Therapies Market: Distribution by Target Indication
      • CAR-T Cell Therapies Market: Distribution by Target Antigen
      • CAR-T Cell Therapies Market: Distribution by Key Players
  • Product Wise Sales Forecast -2030
    • KYMRIAH (Novartis)
    • YESCARTA (Gilead Sciences)
    • Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
    • BREYANZI / Lisocabtagene Maraleucel / JCAR017JCAR017 (Bristol Myers Squibb / Juno Therapeutics)
    • Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb)
    • Ciltacabtagene Autoleucel / LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen)
  • Clinical Pipeline Product Profiles by Companies
  • Pre-Clinical Pipeline Product Profiles by Companies
  • CAR-T Therapy Regulatory Route To Market
    • EU Regulatory Route To Market
    • US Regulatory Route To Market
  • KOLs View on CAR-T
  • Strategies to reduce Cost of CAR-T
  • Report Methodology

Companies Covered

300+ Companies are covered. Provided list is not exhaustive

·      Actinium Pharmaceuticals
·      Adicet Bio
·      AffyImmune Therapeutics
·      AGC
·      Allife Medical Science and Technology
·      Allogene Therapeutics
·      Amgen
·      Arcellx
·      Asclepius Technology Company Group (Suzhou) Co.
·      Atara Biotherapeutics
·      Autolus
·      Bayer AG
·      Baylor College of Medicine/Kuur Therapeutics {Cell Medica}
·      Beijing Doing Biomedical Co.
·      Beijing Gaobo Biotechnology Co.
·      Beijing Immunochina Medical Science & Technology Co.
·      Beijing Menlo Biotechnology Co.Shaanxi People’s Hospital
·      Beijing TCRCure Biological Technology Co.
·      Bellicum Pharmaceuticals
·      Bioceltech Therapeutics
·      BioNTech
·      bluebird bio
·      BoYuan RunSheng Pharma (Hangzhou) Co.
·      Bristol-Myers Squibb/Celgene/Juno Therapeutics
·      Carbiogene Therapeutics Co.
·      Caribou Biosciences
·      Carisma Therapeutics
·      CARsgen Therapeutics
·      Cartesian Therapeutics
·      Cellectis
·      Cellex Patient Treatment
·      Cellular Biomedicine Group
·      Celyad Oncology
·      Cheetah Cell Therapeutics Co.
·      China Beijing Immunochina Medical Science & Technology Co.
·      China Immunotech Co.
·      China National Biotec Group Company
·      ChinaCellular Biomedicine Group
·      Chongqing Precision Biotech
·      CRISPR Therapeutics
·      Curocell Inc.
·      Cytocraft Biotech
·      Eureka Therapeutics
·      Fapon Biotech
·      Fate Therapeutics
·      Fundamenta Therapeutics
·      Gilead Sciences
·      Gilead Sciences/Kite Pharma
·      Gracell Biotechnologies
·      Guangdong Zhaotai InVivo Biomedicine Co.
·      Guangzhou Anjie Biomedical Technology Co.
·      Guangzhou Bio-gene Technology Co.
·      Hangzhou Converd Co.
·      Hebei Senlang Biotechnology Co.
·      Hrain Biotechnology
·      Huadao (Shanghai) Pharmaceutical Co.
·      iCarTAB BioMed
·      iCell Gene Therapeutics
·      iCell Gene Therapeutics/iCAR Bio Therapeutics
·      ImmuFuCell Biotechnology Co.
·      Immune Cell Therapy
·      Immunotech Biopharm//Beijing Immunotech Applied Science Limited
·      Incyte Corporation
·      Innovative Cellular Therapeutics Co.
·      Jiangsu Pacific Meinuoke Bio Pharmaceutical Co.
·      Johnson & Johnson
·      Juventas Cell Therapy
·      JW Therapeutics/Shanghai Mingju Biotechnology Co.
·      Kecellitics Biotech Company
·      Marino Biotechnology Co.
·      MaxCyte
·      Miltenyi Biomedicine
·      Miltenyi Biotec
·      Minerva Biotechnologies
·      Mustang Bio {Fortress Biotech/Mustang Bio}
·      Nanjing Bioheng Biotech Co.
·      Nanjing CART Medical Technologies
·      Nanjing Iaso Biotherapeutics
·      Nanjing KAEDI Biotech
·      Nanjing Legend Biotechnology Co.
·      NantWorks/ImmunityBio
·      Nkarta
·      Novartis
·      Novartis/ Intellia Therapeutics
·      Nuo Therapeutics {Cytomedix}
·      Otsuka Pharmaceutical
·      Otsuka Pharmaceutical/Takara Bio
·      Parasol Biotech Co.
·      PeproMene Bio
·      PersonGen BioTherapeutics
·      Pinze Lifetechnology Co.
·      Poseida Therapeutics
·      Precigen, Inc
·      Precision BioSciences
·      Qilu Cell Therapy Technology Co.
·      Sabz Biomedicals
·      Sangamo Therapeutics {Sangamo BioSciences}Sangamo Therapeutics/TxCell
·      Servier
·      Shanghai Biomed-Union Biotechnology Co.
·      Shanghai Biomed-Union Biotechnology Co./Shanghai Keqi Pharmaceutical Technology Co.
·      Shanghai Bioray Laboratory
·      Shanghai Cell Therapy Group Co.
·      Shanghai Cell Therapy Group Co./Shanghai Cell Therapy Engineering Technology Research Center Group Co.
·      Shanghai Genbase Biotechnology Co.
·      Shanghai Iaso Biotechnology Co.
·      Shanghai Longyao Biotechnology
·      Shanghai Mingju Biotechnology Co.
·      Shanghai Origincell Medicine Co.
·      Shanghai PerHum Therapeutics Co. {Shanghai Sinobioway Sunterra Biotechnology Co.} (Sinobioway Group, Sunterra Capital and F1 Oncology joint venture)
·      Shanghai Pharmaceuticals Holding Co.
·      Shanghai Simnova Biotechnology Co.
·      Shanghai Ultra-T Immune Therapeutics Co.
·      Shanghai Unicar-Therapy Biomed
·      Shanghai Yihao Biotechnology Co.
·      Shengyan Pharmaceutical Technology (Wuhan) Co.
·      Shenzhen BinDeBio
·      Simcere Pharmaceutical Group / Beijing Immunochina Medical Science & Technology Co.
·      Sinobioway Cell Therapy Co.
·      Sobi {Swedish Orphan Biovitrum}
·      Sorrento Therapeutics
·      Sorrento Therapeutics/Scilex Pharmaceuticals
·      Sunnycell Therapeutics
·      Suzhou Maximum Bio-tech
·      Takeda
·      Targeted Onco-Immunologics
·      Tessa Therapeutics
·      The Pregene (Shen Zhen) Biotechnology Company
·      Tianjin Mycure Medical Technology Co.
·      Timmune Biotech
·      Tmunity Therapeutics
·      UWELL Biopharma
·      Weill Cornell Medical College Cellectis
·      Wellington Zhaotai Therapies
·      Wuhan Bio-Raid Biotechnology
·      Wuhan Jinyitai Biological Co.
·      Wuhan Sian Medical Technology
·      Xi’an Yufan Biotechnologies Co.
·      Xinqiao Hospital of Chongqing/Chongqing Precision Biotech Co.
·      Xinqiao Hospital of Chongqing/Gracell Biotechnologies (Shanghai) Co.
·      Yake Biotechnology
·      ZIOPHARM Oncology

 

Name
Email
Phone
Enquiry

You may also like…

Get In Touch

Let's keep the conversation going